137 related articles for article (PubMed ID: 37441347)
1. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma.
Piccinelli ML; Tappero S; Cano Garcia C; Barletta F; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Briganti A; Chun FKH; Terrone C; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Open Sci; 2023 Jul; 53():109-115. PubMed ID: 37441347
[TBL] [Abstract][Full Text] [Related]
2. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients.
Piccinelli ML; Barletta F; Tappero S; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Chun FKH; Terrone C; Briganti A; de Cobelli O; Musi G; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):799-806. PubMed ID: 37024421
[TBL] [Abstract][Full Text] [Related]
3. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
[TBL] [Abstract][Full Text] [Related]
4. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
[TBL] [Abstract][Full Text] [Related]
5. Comparison and validation of different risk models for papillary renal cell carcinoma.
Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
[TBL] [Abstract][Full Text] [Related]
6. Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma.
Piccinelli ML; Morra S; Tappero S; Cano Garcia C; Barletta F; Incesu RB; Scheipner L; Baudo A; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Carmignani L; Ahyai S; Tilki D; Briganti A; Chun FKH; Terrone C; Longo N; de Cobelli O; Musi G; Karakiewicz PI
Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046815
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.
Rosiello G; Larcher A; Fallara G; Giancristofaro C; Martini A; Re C; Cei F; Musso G; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Salonia A; Necchi A; Raggi D; Briganti A; Montorsi F; Capitanio U
Urol Oncol; 2022 Jun; 40(6):271.e19-271.e27. PubMed ID: 35140049
[TBL] [Abstract][Full Text] [Related]
8. A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.
Hu Y; Xu S; Qi Q; Wang X; Meng J; Zhou J; Hao Z; Liang Q; Feng X; Liang C
Front Public Health; 2022; 10():989566. PubMed ID: 36276376
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
10. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients.
Buti S; Karakiewicz PI; Bersanelli M; Capitanio U; Tian Z; Cortellini A; Taguchi S; Briganti A; Montorsi F; Leonardi F; Bandini M
Sci Rep; 2019 Sep; 9(1):13218. PubMed ID: 31519981
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
[TBL] [Abstract][Full Text] [Related]
12. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.
Nocera L; Collà Ruvolo C; Stolzenbach LF; Wenzel M; Tian Z; Larcher A; Capitanio U; Mirone V; Tilki D; Chun FKH; Kapoor A; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):182-190. PubMed ID: 33653677
[TBL] [Abstract][Full Text] [Related]
13. Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma.
Khene ZE; Bigot P; Doumerc N; Ouzaid I; Boissier R; Nouhaud FX; Albiges L; Bernhard JC; Ingels A; Borchiellini D; Kammerer-Jacquet S; Rioux-Leclercq N; Roupret M; Acosta O; De Crevoisier R; Bensalah K;
Eur Urol Oncol; 2023 Jun; 6(3):323-330. PubMed ID: 35987730
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Effect of Subclassification on Oncological Outcomes in Patients with Surgically Treated Localized Papillary Renal Cell Carcinoma: A Retrospective Propensity Score-matched Cohort Study.
Li S; Liu X; Chen X
J Cancer; 2022; 13(4):1193-1202. PubMed ID: 35281881
[No Abstract] [Full Text] [Related]
15. Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma.
Zhanghuang C; Wang J; Yao Z; Li L; Xie Y; Tang H; Zhang K; Wu C; Yang Z; Yan B
Front Public Health; 2022; 10():874427. PubMed ID: 35444972
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma.
Guo P; Wang Y; Han Y; Wei D; Zhao J; Li M; Jiang Y; Luo Y
Urol Oncol; 2021 Dec; 39(12):835.e19-835.e27. PubMed ID: 34620554
[TBL] [Abstract][Full Text] [Related]
19. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
20. Prognostic models of survival in patients with advanced incurable cancer: the PiPS2 observational study.
Stone P; Kalpakidou A; Todd C; Griffiths J; Keeley V; Spencer K; Buckle P; Finlay DA; Vickerstaff V; Omar RZ
Health Technol Assess; 2021 May; 25(28):1-118. PubMed ID: 34018486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
